The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enhancing radioiodine (RAI) incorporation into BRAFV600E-mutant, RAI-refractory thyroid cancers with the BRAF inhibitor vemurafenib: A pilot study.
 
Lara Dunn
No Relationships to Disclose
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Bayer/Onyx; Eisai; Novartis
 
Shrujal S. Baxi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca
 
Ravinder K. Grewal
No Relationships to Disclose
 
Keith S. Pentlow
No Relationships to Disclose
 
Sofia Haque
No Relationships to Disclose
 
R. Michael Tuttle
Consulting or Advisory Role - Eisai; Genzyme
 
Mona Sabra
No Relationships to Disclose
 
Stephanie Fish
No Relationships to Disclose
 
Laura Boucai
No Relationships to Disclose
 
Ai Ni
No Relationships to Disclose
 
Jeffrey Knauf
No Relationships to Disclose
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca; Bayer; Boehringer Ingelheim; Exelixis; Genentech; GlaxoSmithKline; Lilly; MedImmune; Merck; Novartis
 
James A. Fagin
Consulting or Advisory Role - Chugai Pharma
Research Funding - Eisai
Travel, Accommodations, Expenses - Chugai Pharma
 
Alan Loh Ho
Honoraria - Novartis
Consulting or Advisory Role - Eisai; Novartis
Research Funding - AstraZeneca; Bayer; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly
Travel, Accommodations, Expenses - Janssen Oncology